The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer (Webinar Audio Proceedings)

Listen to streaming audioright from your computer
Download programto your desktop
Sign up for podcastto have this and future issues delivered to your iTunes library

Audio Highlights

Track 1:	Introduction
Track 2:	Immune checkpoint inhibitors for non-muscle-invasive urothelial bladder cancer (UBC)
Track 3:	Immune checkpoint inhibitors as neoadjuvant/adjuvant therapy for muscle-invasive UBC
Track 4:	Immune checkpoint inhibitors in advanced UBC
Track 5:	Current and future roles of recently FDA-approved novel therapies

FACULTY

Arjun Balar, MD
Associate Professor
Department of Medicine
Director, Genitourinary Medical Oncology Program
NYU Perlmutter Cancer Center
New York, New York

Siamak Daneshmand, MD
Associate Professor of Urology (Clinical Scholar)
Director of Urologic Oncology
Director of Clinical Research
Urologic Oncology Fellowship Director
USC/Norris Comprehensive Cancer Center
Institute of Urology
Los Angeles, California

Ashish M Kamat, MD, MBBS
Professor of Urologic Oncology (Surgery)
Wayne B Duddlesten Professor of Cancer Research
Department of Urology
Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jonathan E Rosenberg, MD
Chief
Genitourinary Medical Oncology Service
Division of Solid Tumor Oncology
Enno W Ercklentz Chair
Memorial Sloan Kettering Cancer Center
New York, New York

MODERATOR

Neil Love, MD
Research To Practice
Miami, Florida